Core Viewpoint - Insulet Corporation is under investigation for potential violations of federal securities laws following a defect in its Omnipod 5 product that could lead to serious medical emergencies [1][3]. Group 1: Company Performance and Statements - During the February 18 earnings call, Insulet's executives highlighted strong clinical evidence and real-world outcomes that bolstered confidence among prescribers and patients, with Omnipod 5 being described as the "favorite pump" for both type-1 and type-2 users in 2025 [2]. - CFO Flavia Pease reported that U.S. revenue growth exceeded the high end of the company's guidance range, driven by continued demand for Omnipod 5 among type 1 and type 2 customers [2]. Group 2: Product Issues - A March 12 filing disclosed a defect in Omnipod 5 Pods, specifically insulin leakage that could result in diabetic ketoacidosis, a serious medical emergency [3]. - The statements made by Insulet's executives on February 18 regarding the reliability of Omnipod and patient confidence did not mention any product-quality issues or potential recalls [3].

Key Takeaways Insulet gains from strong Omnipod 5 adoption, driving solid U.S. and international revenue growth.PODD benefits from a large underpenetrated diabetes market and expanding insulin pump adoption globally.Macroeconomic uncertainty, supply risks and intense competition may pressure Insulet's growth.Insulet (PODD) is well-poised to grow in the upcoming quarters, owing to its strong momentum for the Omnipod 5 automated insulin delivery (“AID”) system for both Type 1 and Type 2 populations. The diabe ...

Core Insights - Insulet Corporation reported strong fourth-quarter earnings and revenue growth, with adjusted earnings per share of $1.55, up 34.8% year-over-year, surpassing estimates by 4.87% [3] - The company’s revenues for Q4 reached $783.8 million, exceeding estimates by 2.15% and reflecting a year-over-year increase of 31.2% [4] Financial Performance - Insulet's full-year 2025 earnings per share were $4.97, a 53.4% increase from the previous year, also surpassing estimates by 1.2% [3] - The gross profit for Q4 was $568.6 million, up 31.9% year-over-year, with a gross margin of 72.5%, expanding by 32 basis points [6] - Operating profit for the quarter was $146.3 million, reflecting a 33.7% increase year-over-year, with an operating margin of 18.7%, up 36 basis points [7] Revenue Breakdown - Total Omnipod revenues for Q4 were $781.8 million, a 33.5% increase year-over-year, with international revenues rising 50.7% [5] - The Drug Delivery business reported revenues of $2 million, down 83.4% year-over-year [5] Cash Position - Insulet ended Q4 2025 with cash and cash equivalents of $716.1 million, down from $953.4 million at the end of 2024, but cumulative net cash from operating activities increased to $569.3 million from $430.2 million year-over-year [8] Future Outlook - For full-year 2026, Insulet projects total revenue growth of 20%-22% at constant exchange rates, with Omnipod revenue growth expected at 21%-23% [10] - The company anticipates a decline of approximately 50% in Drug Delivery revenues at constant exchange rates [10] - For Q1 2026, revenue growth is projected at 25%-27%, with Omnipod revenues expected to rise 28%-30% [11] Market Position - Insulet has a strong Growth Score of A, but a B on the Momentum Score, indicating mixed performance in different investment strategies [13] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [14]

PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky Accessibility StatementSkip NavigationInsulet CEO Called Omnipod 5 "Reliable" and a "Favorite Pump" on February 18 -- Two Weeks Later, the Company Disclosed a Voluntary Recall Covering Thousands of Defective PodsNEW YORK, March 18, 2026 /PRNewswire/ -- On February 18, 2026, Insulet Corp. (NASDAQ: PODD) CEO Ashley McEvoy ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Insulet Corporation ("Insulet†or the "Company†) (NASDAQ: PODD) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON INSULET CORPORATION (PODD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On March 12, 2026, Insulet disclosed that it had "initiated a vo. ...

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Insulet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 12 ...

Core Viewpoint - Insulet Corporation is under investigation for potential violations of federal securities laws following a defect in its Omnipod 5 product that was not disclosed during a previous earnings call [1][3]. Group 1: Company Performance and Statements - During the February 18 earnings call, Insulet's CEO McEvoy highlighted strong clinical evidence and real-world outcomes that bolstered confidence among prescribers and patients, referring to Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025 [2]. - CFO Flavia Pease reported that U.S. revenue growth exceeded the high end of the company's guidance range, driven by continued demand for Omnipod 5 among type 1 and type 2 customers [2]. - No mention was made of product quality issues, pending regulatory actions, or anticipated recalls during the earnings call [2]. Group 2: Product Issues - A March 12 filing revealed a defect in Omnipod 5 Pods, specifically insulin leakage that could lead to diabetic ketoacidosis, a serious medical emergency [3]. - The statements made by Insulet on February 18 regarding the reliability of Omnipod and patient confidence did not address these critical issues [3].

Core Viewpoint - Glancy Prongay Wolke & Rotter LLP has initiated an investigation into Insulet Corporation regarding potential violations of federal securities laws affecting investors [1] Group 1 - The investigation is on behalf of Insulet Corporation investors who may have incurred financial losses [1] - The law firm is encouraging affected investors to inquire about pursuing claims to recover their losses [1]

Core Viewpoint - Insulet Corporation is under investigation for potential violations of federal securities laws, which may impact investors who have suffered losses [1] Group 1 - The Law Offices of Howard G. Smith are representing Insulet Corporation investors in this investigation [1] - Investors who experienced financial losses in Insulet Corporation (NASDAQ: PODD) are encouraged to contact the law firm regarding possible claims [1]

Core Viewpoint - Insulet Corporation is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Group 1: Investigation Details - The Law Offices of Frank R. Cruz announced the investigation on behalf of investors [1] - The investigation is focused on Insulet's disclosures made on March 12, 2026, regarding its operations [1]